Specific inhibitors prevent proteolytic degradation of recombinant proteins expressed in High Five cells.
The insect cell line BTI-TN-5B1-4 (High Five) is frequently used to express recombinant proteins in large amounts using the baculovirus expression system. However, extensive proteolytic degradation of recombinant proteins is often encountered. Furthermore, we have observed that recombinant proteins migrate in SDS-PAGE in agreement with poly-ubiquitinated forms of the protein, suggesting a ubiquitin/proteasome degradation pathway. Here, we describe a systematic study unraveling the effect of adding proteasome inhibitors or specific protease inhibitors to the growth medium of High Five insect cells infected with recombinant baculovirus. Furthermore, protease inhibitors were added to the lysis buffer to establish the most efficient way to inhibit proteolytic activity after lysis of baculovirus-infected cells expressing recombinant proteins. We conclude that a combination of adding protease inhibitors to the growth medium and to the lysis buffer minimizes the proteolytic activity in High Five cells. The most efficient protease inhibitors were E-64 in the growth medium together with Leupeptin in the lysis buffer at concentrations higher than with available cocktails of inhibitors. The optimal treatment of High Five cells is different from the optimal treatment of Sf9 cells. For proteins susceptible to ubiquitinylation, a treatment of insect cell cultures with the proteasome inhibitor MG132 (LLL) leads to a considerable reduction of the yield of production of recombinant protein.
Martensen
P M
PM
Department of Molecular and Structural Biology, University of Aarhus, C.F. Mollers Allé blgd. 130, 8000 Aarhus C, Denmark. pips@biobase.dk
Justesen
J
J
D000818:Animals; D016367:Baculoviridae / Q000235:genetics; D002460:Cell Line; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology*; D005822:Genetic Vectors; D007313:Insecta; D007930:Leucine / Q000031:analogs & derivatives* / Q000494:pharmacology; D007976:Leupeptins / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000235:genetics* / Q000378:metabolism*; D014162:Transfection
D015853:Cysteine Proteinase Inhibitors; D007976:Leupeptins; D011994:Recombinant Proteins; D007930:Leucine; C032854:leupeptin; C024974:E 64; C072553:benzyloxycarbonylleucyl-leucyl-leucine aldehyde